(Q37611687)

English

Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients

scientific article published on 03 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Bernard Vrijens

object named as

B Vrijens

8

0 references

author name string

R M Savic

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

A Barrail-Tran

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

X Duval

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

G Nembot

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

X Panhard

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

D Descamps

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

C Verstuyft

7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

A-M Taburet

9

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

C Goujard

10

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

F Mentré

11

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

ANRS 134–COPHAR 3 Study Group

12

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

language of work or name

0 references

publication date

3 October 2012

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

92

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

575-583

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Risk factors for gastrointestinal adverse events in HIV treated and untreated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Atazanavir: a novel HIV-1 protease inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

6 September 2017

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

25 June 2018

Comparing compliance patterns between randomized treatments.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

25 June 2018

A population pharmacokinetic-pharmacogenetic analysis of atazanavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Modelling the association between adherence and viral load in HIV-infected patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

The impact of compliance in pharmacokinetic studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Chronobiology. Suggestions for integrating it into drug development

1 reference

https://pubmed.ncbi.nlm.nih.gov/23033116

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/CLPT.2012.137

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37611687&oldid=2133323248"